A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?
Over the last decades, a revolution has occurred in oncology with the development of immune checkpoint inhibitors (ICIs). Following tremendous successes in solid tumors, interest has risen to explore these inhibitors in hematologic malignancies; while Hodgkin's lymphoma (HL) has shown overwhelm...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523323000220 |
| _version_ | 1797902944520110080 |
|---|---|
| author | Zeinab Davoodi-Moghaddam Farideh Jafari-Raddani Maryam Noori Davood Bashash |
| author_facet | Zeinab Davoodi-Moghaddam Farideh Jafari-Raddani Maryam Noori Davood Bashash |
| author_sort | Zeinab Davoodi-Moghaddam |
| collection | DOAJ |
| description | Over the last decades, a revolution has occurred in oncology with the development of immune checkpoint inhibitors (ICIs). Following tremendous successes in solid tumors, interest has risen to explore these inhibitors in hematologic malignancies; while Hodgkin's lymphoma (HL) has shown overwhelming achievements, available data on different types of non-Hodgkin's lymphoma (NHL) vary considerably. To the best of our knowledge, no meta-analysis has assessed the efficacy and safety of ICI therapy in relapsed or refractory NHL patients. Meta-analysis of the included studies (n = 29) indicated PD-1 may probably be the more attractive ICI target rather than PD-L1 and CTLA-4 in NHL patients. Also, there is a plausible correlation between NHL subtypes and response to ICI therapy. While MF, ENKTL, RT, and PMBCL showed promising responses to ICI monotherapy, neither FL nor DLBCL had satisfactory responses; further necessitating novel strategies such as the application of ICIs in combination with other treatment strategies. Notably, among different combinations, BTK inhibitors showed an obvious improvement as compared to ICI monotherapy in both FL and DLBCL, however, the best results were obtained when ICI was combined with anti-CD20 monoclonal antibodies. Finally, while most NHL patients who received ICI treatment have experienced mild AEs, larger trials with long-term follow-up are required to confirm the safety, as well as the efficacy, of ICI therapy in NHL patients. |
| first_indexed | 2024-04-10T09:25:12Z |
| format | Article |
| id | doaj.art-34807039694f4864a3bb922771ca4287 |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-04-10T09:25:12Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-34807039694f4864a3bb922771ca42872023-02-20T04:08:59ZengElsevierTranslational Oncology1936-52332023-04-0130101636A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?Zeinab Davoodi-Moghaddam0Farideh Jafari-Raddani1Maryam Noori2Davood Bashash3Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IranStudent Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Urology Research Center, Tehran University of Medical Sciences, Tehran, IranDepartment of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Corresponding author.Over the last decades, a revolution has occurred in oncology with the development of immune checkpoint inhibitors (ICIs). Following tremendous successes in solid tumors, interest has risen to explore these inhibitors in hematologic malignancies; while Hodgkin's lymphoma (HL) has shown overwhelming achievements, available data on different types of non-Hodgkin's lymphoma (NHL) vary considerably. To the best of our knowledge, no meta-analysis has assessed the efficacy and safety of ICI therapy in relapsed or refractory NHL patients. Meta-analysis of the included studies (n = 29) indicated PD-1 may probably be the more attractive ICI target rather than PD-L1 and CTLA-4 in NHL patients. Also, there is a plausible correlation between NHL subtypes and response to ICI therapy. While MF, ENKTL, RT, and PMBCL showed promising responses to ICI monotherapy, neither FL nor DLBCL had satisfactory responses; further necessitating novel strategies such as the application of ICIs in combination with other treatment strategies. Notably, among different combinations, BTK inhibitors showed an obvious improvement as compared to ICI monotherapy in both FL and DLBCL, however, the best results were obtained when ICI was combined with anti-CD20 monoclonal antibodies. Finally, while most NHL patients who received ICI treatment have experienced mild AEs, larger trials with long-term follow-up are required to confirm the safety, as well as the efficacy, of ICI therapy in NHL patients.http://www.sciencedirect.com/science/article/pii/S1936523323000220Immune checkpoint inhibitorImmunotherapyNon-Hodgkin lymphomaPD-1PD-LCTLA-4 |
| spellingShingle | Zeinab Davoodi-Moghaddam Farideh Jafari-Raddani Maryam Noori Davood Bashash A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe? Translational Oncology Immune checkpoint inhibitor Immunotherapy Non-Hodgkin lymphoma PD-1 PD-L CTLA-4 |
| title | A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe? |
| title_full | A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe? |
| title_fullStr | A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe? |
| title_full_unstemmed | A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe? |
| title_short | A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe? |
| title_sort | systematic review and meta analysis of immune checkpoint therapy in relapsed or refractory non hodgkin lymphoma a friend or foe |
| topic | Immune checkpoint inhibitor Immunotherapy Non-Hodgkin lymphoma PD-1 PD-L CTLA-4 |
| url | http://www.sciencedirect.com/science/article/pii/S1936523323000220 |
| work_keys_str_mv | AT zeinabdavoodimoghaddam asystematicreviewandmetaanalysisofimmunecheckpointtherapyinrelapsedorrefractorynonhodgkinlymphomaafriendorfoe AT faridehjafariraddani asystematicreviewandmetaanalysisofimmunecheckpointtherapyinrelapsedorrefractorynonhodgkinlymphomaafriendorfoe AT maryamnoori asystematicreviewandmetaanalysisofimmunecheckpointtherapyinrelapsedorrefractorynonhodgkinlymphomaafriendorfoe AT davoodbashash asystematicreviewandmetaanalysisofimmunecheckpointtherapyinrelapsedorrefractorynonhodgkinlymphomaafriendorfoe AT zeinabdavoodimoghaddam systematicreviewandmetaanalysisofimmunecheckpointtherapyinrelapsedorrefractorynonhodgkinlymphomaafriendorfoe AT faridehjafariraddani systematicreviewandmetaanalysisofimmunecheckpointtherapyinrelapsedorrefractorynonhodgkinlymphomaafriendorfoe AT maryamnoori systematicreviewandmetaanalysisofimmunecheckpointtherapyinrelapsedorrefractorynonhodgkinlymphomaafriendorfoe AT davoodbashash systematicreviewandmetaanalysisofimmunecheckpointtherapyinrelapsedorrefractorynonhodgkinlymphomaafriendorfoe |